<DOC>
	<DOCNO>NCT02548195</DOCNO>
	<brief_summary>To evaluate adjuvant therapy use oxaliplatin gemcitabine ( GEMOX regimen ) versus capecitabine alone chemotherapy patient underwent curative surgery intrahepatic cholangiocarcinoma ( ICC ) -- randomize control study .</brief_summary>
	<brief_title>Oxaliplatin+Gemcitabine v Capecitabine Adjuvant Therapy Intrahepatic Cholangiocarcinoma</brief_title>
	<detailed_description>chemotherapy : GEMOX v capecitabine alone ; adjuvant setting ; primary endpoint : recurrence-free survival ( RFS ) ; second endpoint : overall survival surgery ( OS ) .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>ECOG PSâ‰¤1 ; pathologically confirm adenocarcinoma bile duct ; R1 resection R0 resection risk factor : lymph node metastasis , lymphatic vessel blood vessel invasion , multiple tumor , tumor size &gt; 5 cm , preoperative CA199 &gt; 200 U/mL . postoperative liver function Child Pugh Class A , leukocyte count &gt; 1.5*10^9/L , platelet count &gt; 100*10^9/L , serum alanine aminotransferase &lt; 1.5*ULN tumor recurrence metastasis baseline examination history radiotherapy intervention therapy hepatocellular carcinoma , mixed carcinoma ICC HCC , hilar cholangiocarcinoma distant metastasis prothrombin time &gt; 14 severe cardiopulmonary dysfunction severe renal dysfunction bone marrow suppression initiation therapy allergic fluorouracil , gemcitabine , platinum gemcitabine use combination radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>GEMOX</keyword>
	<keyword>intrahepatic cholangiocarcinoma</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>capecitabine</keyword>
	<keyword>curative surgery</keyword>
</DOC>